503A pharmacy regulations: the DQSA framework explained

The Drug Quality and Security Act is the law that decides what compounded medicine looks like. Here is the plain-English version.

TL;DR

• The DQSA (Drug Quality and Security Act) is the 2013 federal law that defines 503A and 503B compounding.
• It exists because a 2012 contamination outbreak killed 64 people. Congress wrote rules to make sure it would not happen again.
• The DQSA is what makes patient-specific peptide compounding legal — and also what limits which peptides 503A pharmacies can use.

What it is

DQSA stands for the Drug Quality and Security Act, signed into law in November 2013. It is a federal statute (in plain English: a written law passed by Congress and signed by the President) with two main jobs. The first is to formalize the rules around compounded medicine — who can make it, for whom, and under what oversight. The second is to track and trace prescription drugs from manufacture to dispense. Section 503A is the part most peptide patients run into first.

How it works

Think of the DQSA as the building code for the compounding industry. Before 2013, the rules were patchy. Some pharmacies operated like factories without factory-level oversight. The DQSA put up clear walls. 503A pharmacies are the tailor lane: one prescription, one patient, regulated by state boards of pharmacy. 503B outsourcing facilities are the small-factory lane: batch compounding under FDA inspection. The law also gave the FDA a job — keep a list of bulk drug substances that 503A pharmacies are allowed to use, with a process for adding new ones and removing risky ones.

Who asks about it

People come to this topic when they read that a peptide they wanted was “moved to Category 2” or that some peptides got “banned in 2023.” The DQSA is the underlying machinery behind those headlines. Understanding the framework makes the news stop sounding random — it is a list, a process, and a periodic review, not a coin flip.

What the research says

The DQSA was a direct policy response to the New England Compounding Center disaster, in which contaminated steroid injections caused a multistate fungal meningitis outbreak. About 64 patients died and roughly 750 were sickened, per CDC’s outbreak summary (CDC, 2013). Congress passed the DQSA the following year (H.R. 3204, 113th Congress). The FDA has since published guidance documents covering bulk substance lists, compounding standards, and the conditions under which a 503A pharmacy may compound an “essentially a copy” of a commercial product (FDA Compounding Policy). The picture in 2026 is more structured than it was a decade ago.

What to know before considering it

The DQSA does not make any specific compounded medication “FDA-approved.” It defines the legal sandbox. Within that sandbox, individual peptides move on and off the allowable list as the FDA evaluates their safety and characterization data. That is why some peptides are widely available through 503A pharmacies and others are not. Quality between pharmacies still varies. Accreditation (like PCAB) and independent potency testing are reasonable signals.

The Halftime POV

The DQSA is not exciting reading, but it is load-bearing. Every legitimate compounded peptide prescription in the United States traces back to it. Knowing the framework changes the conversation from “is this legal?” to “where does this specific compound sit in the framework?” That is a much more useful question and a much better starting point for an honest discussion with a clinician.

Related reading:

• 503A vs 503B compounding: the functional difference
• How the FDA categorizes peptides for 503A compounding
• The ‘banned overnight’ myth: what actually happened to peptides in 2023

FAQ

Q: What is the DQSA? A: The Drug Quality and Security Act is a 2013 federal law that defines how pharmacies are allowed to compound medications and what oversight applies.

Q: Why was the DQSA written? A: It followed the 2012 New England Compounding Center meningitis outbreak, which killed 64 people and exposed gaps in compounding oversight.

Q: Does the DQSA make 503A compounding FDA-approved? A: No. It defines the legal scope of what 503A pharmacies can compound, but the compounded products themselves are not FDA-approved drugs.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• FDA: Human Drug Compounding Regulatory Policy
• Drug Quality and Security Act (H.R. 3204), 113th Congress
• CDC: Multistate Outbreak of Fungal Meningitis Linked to NECC, 2013